Reaction
Immune-Mediated Hypophysitis reporting signals
As of the last recalculation, Immune-Mediated Hypophysitis appears in 423 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 336.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ipilimumab | 174 | 336.3 | 337.6 |
| Nivolumab | 212 | 215.3 | 215.8 |
| Pembrolizumab | 176 | 140.3 | 140.5 |
| Carboplatin | 91 | 44.6 | 44.7 |
| Paclitaxel (Aibumin-Bound) | 60 | 41.7 | 41.7 |
| Durvalumab | 16 | 40.2 | 40.2 |
| Paclitaxel | 61 | 35.2 | 35.3 |
| Pemetrexed | 13 | 30.7 | 30.8 |
| Lenvatinib | 14 | 21.7 | 21.7 |
| Encorafenib | 3 | 15.0 | 15.0 |